Head and Neck Cancer clinical trials in Rhode Island

2 actively recruiting head and neck cancer trials at 1 site across Rhode Island.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Calico Life Sciences LLC funds and runs this clinical trial (NCT04777994). In 2024, Calico Life Sciences LLC reported paying the doctors leading the trial a total of $1,819,797 for research work on this study.

Who paid

ABBVIE INC. $1,819,797

Paid for research work on this trial

BENEDITO CARNEIRO FILHO(oncologist on CancerDrs) $423,763
ULKA VAISHAMPAYAN(oncologist on CancerDrs) $310,128
KARTIK SEHGAL(oncologist on CancerDrs) $225,935
JASON LUKE(oncologist on CancerDrs) $169,037
DAVID SOMMERHALDER(oncologist on CancerDrs) $166,261

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca

NCT ID: NCT07431281

Sites in Rhode Island:

Research Site — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…

Sponsor: Calico Life Sciences LLC

NCT ID: NCT04777994

Sites in Rhode Island:

Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705 — Providence, Rhode Island

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01